BLUE up 7% after FDA approval 💉

Shares of Bluebird Bio (BLUE) are trading 7% higher at a price of $7.03 at the time of this writing. So far the Health Care sector has been having a "meh" day, and the share price of the company is flying past it's peers.

The price is likely moving on the heels of the recent earnings call on August 09, but more likely it's moving on recent news that the FDA has approved Bluebird's gene therapy for beta thalassemia.

Bluebird Bio has been trading between a 52-week high of $17.85 and a 52-week low of $2.87. The stock has a market cap of $542 Million.

bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.